Blum Murphy MA, et al. - Given that docetaxel, cisplatin, and 5-fluorouracil (DCF)-related toxicity limits its use in patients with untreated advanced gastric cancer (AGC) despite its being established as one of the standard treatments for these patients in a randomized phase III study, researchers assessed a less toxic regimen ie, a modified DCF (oxaliplatin, 5-fluorouracil, and docetaxel [D-FOX]) for untreated AGC patients in this single arm, phase I/II trial. Maximum tolerated dose of docetaxel in phase I study and progression-free survival (PFS) at 6 months and overall survival (OS) in phase II study were determined. The maximum tolerated dose of docetaxel was 50 mg/m². When administered every 2 weeks, D-FOX was well-tolerated and represented an active regimen in untreated AGC patients. The median PFS was approximately 6.5 months and the median OS was 11.1 months.